These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29169478)

  • 1. 2017 Roadmap for Innovation-ACC Health Policy Statement on Healthcare Transformation in the Era of Digital Health, Big Data, and Precision Health: A Report of the American College of Cardiology Task Force on Health Policy Statements and Systems of Care.
    Bhavnani SP; Parakh K; Atreja A; Druz R; Graham GN; Hayek SS; Krumholz HM; Maddox TM; Majmudar MD; Rumsfeld JS; Shah BR
    J Am Coll Cardiol; 2017 Nov; 70(21):2696-2718. PubMed ID: 29169478
    [No Abstract]   [Full Text] [Related]  

  • 2. ACC/AHA/STS Statement on the Future of Registries and the Performance Measurement Enterprise: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and The Society of Thoracic Surgeons.
    Bhatt DL; Drozda JP; Shahian DM; Chan PS; Fonarow GC; Heidenreich PA; Jacobs JP; Masoudi FA; Peterson ED; Welke KF
    J Am Coll Cardiol; 2015 Nov; 66(20):2230-2245. PubMed ID: 26440214
    [No Abstract]   [Full Text] [Related]  

  • 3. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
    January CT; Wann LS; Alpert JS; Calkins H; Cigarroa JE; Cleveland JC; Conti JB; Ellinor PT; Ezekowitz MD; Field ME; Murray KT; Sacco RL; Stevenson WG; Tchou PJ; Tracy CM; Yancy CW;
    Circulation; 2014 Dec; 130(23):2071-104. PubMed ID: 24682348
    [No Abstract]   [Full Text] [Related]  

  • 4. 2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.
    Al-Khatib SM; Yancy CW; Solis P; Becker L; Benjamin EJ; Carrillo RG; Ezekowitz JA; Fonarow GC; Kantharia BK; Kleinman M; Nichol G; Varosy PD
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):e000022. PubMed ID: 27993943
    [No Abstract]   [Full Text] [Related]  

  • 5. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Jacobs AK; Anderson JL; Halperin JL
    J Am Coll Cardiol; 2014 Sep; 64(13):1373-84. PubMed ID: 25103073
    [No Abstract]   [Full Text] [Related]  

  • 6. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Bonow RO; Nishimura RA; Thompson PD; Udelson JE
    J Am Coll Cardiol; 2015 Dec; 66(21):2385-2392. PubMed ID: 26542667
    [No Abstract]   [Full Text] [Related]  

  • 7. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension: A Scientific Statement from the American Heart Association and the American College of Cardiology.
    Black HR; Sica D; Ferdinand K; White WB
    J Am Coll Cardiol; 2015 Dec; 66(21):2393-2397. PubMed ID: 26542658
    [No Abstract]   [Full Text] [Related]  

  • 8. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 14: Sickle Cell Trait: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Harris KM; Thompson PD; Eichner ER; Steinberg MH
    J Am Coll Cardiol; 2015 Dec; 66(21):2444-2446. PubMed ID: 26542668
    [No Abstract]   [Full Text] [Related]  

  • 9. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Ackerman MJ; Zipes DP; Kovacs RJ; Maron BJ
    J Am Coll Cardiol; 2015 Dec; 66(21):2424-2428. PubMed ID: 26542662
    [No Abstract]   [Full Text] [Related]  

  • 10. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.
    Anderson JL; Heidenreich PA; Barnett PG; Creager MA; Fonarow GC; Gibbons RJ; Halperin JL; Hlatky MA; Jacobs AK; Mark DB; Masoudi FA; Peterson ED; Shaw LJ
    J Am Coll Cardiol; 2014 Jun; 63(21):2304-22. PubMed ID: 24681044
    [No Abstract]   [Full Text] [Related]  

  • 11. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 4: Congenital Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Van Hare GF; Ackerman MJ; Evangelista JK; Kovacs RJ; Myerburg RJ; Shafer KM; Warnes CA; Washington RL
    J Am Coll Cardiol; 2015 Dec; 66(21):2372-2384. PubMed ID: 26542660
    [No Abstract]   [Full Text] [Related]  

  • 12. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease: A Scientific Statement from the American Heart Association and American College of Cardiology.
    Thompson PD; Myerburg RJ; Levine BD; Udelson JE; Kovacs RJ
    J Am Coll Cardiol; 2015 Dec; 66(21):2406-2411. PubMed ID: 26542666
    [No Abstract]   [Full Text] [Related]  

  • 13. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 13: Commotio Cordis: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Link MS; Estes NAM; Maron BJ
    J Am Coll Cardiol; 2015 Dec; 66(21):2439-2443. PubMed ID: 26542669
    [No Abstract]   [Full Text] [Related]  

  • 14. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Levine BD; Washington RL; Baggish AL; Kovacs RJ; Maron MS
    J Am Coll Cardiol; 2015 Dec; 66(21):2356-2361. PubMed ID: 26542659
    [No Abstract]   [Full Text] [Related]  

  • 15. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Bonow RO; Nishimura RA; Thompson PD; Udelson JE;
    Circulation; 2015 Dec; 132(22):e292-7. PubMed ID: 26621646
    [No Abstract]   [Full Text] [Related]  

  • 16. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Ackerman MJ; Zipes DP; Kovacs RJ; Maron BJ;
    Circulation; 2015 Dec; 132(22):e326-9. PubMed ID: 26527716
    [No Abstract]   [Full Text] [Related]  

  • 17. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 15: Legal Aspects of Medical Eligibility and Disqualification Recommendations: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Mitten MJ; Zipes DP; Maron BJ; Bryant WJ
    J Am Coll Cardiol; 2015 Dec; 66(21):2447-2450. PubMed ID: 26542663
    [No Abstract]   [Full Text] [Related]  

  • 18. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
    Yancy CW; Jessup M; Bozkurt B; Butler J; Casey DE; Drazner MH; Fonarow GC; Geraci SA; Horwich T; Januzzi JL; Johnson MR; Kasper EK; Levy WC; Masoudi FA; McBride PE; McMurray JJ; Mitchell JE; Peterson PN; Riegel B; Sam F; Stevenson LW; Tang WH; Tsai EJ; Wilkoff BL
    Circulation; 2013 Oct; 128(16):1810-52. PubMed ID: 23741057
    [No Abstract]   [Full Text] [Related]  

  • 19. 2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.
    ; Drozda JP; Ferguson TB; Jneid H; Krumholz HM; Nallamothu BK; Olin JW; Ting HH; ; Heidenreich PA; Albert NM; Chan PS; Curtis LH; Ferguson TB; Fonarow GC; Ho PM; O'Brien S; Russo AM; Thomas RJ; Ting HH; Varosy PD
    Circ Cardiovasc Qual Outcomes; 2016 Jan; 9(1):68-95. PubMed ID: 26666514
    [No Abstract]   [Full Text] [Related]  

  • 20. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 11: Drugs and Performance-Enhancing Substances: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Estes NAM; Kovacs RJ; Baggish AL; Myerburg RJ
    J Am Coll Cardiol; 2015 Dec; 66(21):2429-2433. PubMed ID: 26542661
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.